Lundbeck(LUN)
Denmark - CopenhagenPharmaceutical
Focus: Lundbeck is a mid-cap Danish pharmaceutical company with 5,001–10,000 employees focused on neuropsychiatric and neurological conditions. It operates as a public company (ticker: LUN) with a diversified portfolio spanning seizure management, migraine, depression, and rare neurological diseases.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
5001-10000
Open Jobs
0
About Lundbeck
AI assessmentNot HiringNo open roles listed right now. Follow Lundbeck to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Lundbeck's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$32M Part DStable
Peak
Anchors 36% of company revenue; cytochrome P450 2D6 inhibitor with sustained Part D reimbursement.
Help build intelligence for Lundbeck
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.